XORTX Re-Engages IR Agency with $2.5M Non-Refundable Fee After Delisting
XRTX sits 39% above its 52-week low of $1.725 on light trading volume (0.2× avg).
Summary
XORTX Therapeutics entered into a new $2.5 million investor relations agreement with IR Agency LLC, payable in advance and non-refundable, following its voluntary delisting from the TSXV. The agreement includes terms that heavily favor the consultant and come amid the Company's going concern warning.
Key Events · Corporate Governance and Compliance · XRTX
-
New IR Agreement with $2.5M Non-Refundable Fee
On September 2, 2026, XORTX entered into a revised consulting agreement with IR Agency LLC for $2,500,000, payable in advance, for a 3-month term with up to 10 news distribution campaigns. The fee is fully earned upon receipt and non-refundable, including upon termination.
-
Restrictive Terms Favor Consultant
The agreement includes a covenant not to sue, limitation of liability, and indemnification provisions favoring IR Agency. The Company waives any right to refund, offset, or chargeback, and either party may terminate at any time without refund.
-
Delisting from TSXV Completed
The Company received final approval from the TSXV for voluntary delisting, effective September 1, 2026. XORTX continues to be listed on the Nasdaq Capital Market under the symbol XRTX.
-
Financial Distress Context
This agreement follows a $2.5 million net loss for H1 2026, a going concern warning, and a material weakness in internal controls disclosed on August 17, 2026. The Company's market cap is approximately $3.9 million.
Analysis · XRTX · Life Sciences
XORTX Therapeutics has re-engaged IR Agency LLC under a new consulting agreement, committing $2.5 million in advance for a three-month marketing program. The fee is fully earned upon receipt and non-refundable, even if the agreement is terminated, and the Company waives any right to refund, offset, or chargeback. This comes just days after the Company completed its voluntary delisting from the TSX Venture Exchange and amid a going concern warning and material weakness disclosed in August 2026. The non-refundable nature of the payment and the restrictive terms favoring the consultant raise governance concerns, especially given the Company's limited cash runway and recent financial distress.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.8% of the 1618 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XRTX was trading at $2.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.73 to $7.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.